ACO REACH: An Innovative Step Towards Health Equity

By HEOR Staff Writer

October 29, 2023

ACO REACH and health equity

Understanding ACO REACH and its Impact

Launched in January 2023, Accountable Care Organisation Realising Equity, Access, and Community Health (ACO REACH), initiated by the Centers for Medicare and Medicaid Services (CMS), has taken a strategic leap towards equity in healthcare. The model is designed to promote health equity through payment model design, data collection on social drivers of health, and financial incentives linked to equity.

A key feature of ACO REACH is the Health Equity Benchmark Adjustment (HEBA). This adjustment allows for increases or decreases in participants’ financial benchmarks based on the beneficiaries they serve. The goal? To remove the disincentives to serve marginalised populations by acknowledging the extra costs of caring for these groups.

Changes to HEBA Calculations in 2024

As we move into 2024, Medicare is taking on board stakeholder feedback and revising its approach to HEBA calculations. This change is significant, as it marks one of the first attempts to alter financial targets based on non-medical factors.

The way HEBA scores are calculated will also undergo changes. Currently, the HEBA is based on measures of individual beneficiary income and area-level social need. However, from next year, CMS will incorporate beneficiaries’ state ADI, a measure that ranks the social need in a beneficiary’s neighbourhood against the need in other neighbourhoods across a given state.

The implications of these changes are substantial. They represent a pragmatic way to improve policymakers’ ability to identify individuals with low-income and high health-related need.

In conclusion, ACO REACH is one of the first models to reflect a national call to action for health care stakeholders to go beyond traditional approaches to value-based payment and address equity. 

Reference url

Recent Posts

GLP-1 Medication Access
Expanded GLP-1 Medication Access Through Formulary Updates

By HEOR Staff Writer

May 29, 2026

CVS Caremark's latest formulary changes are poised to strengthen GLP-1 Medication Access for commercial plan members by restoring coverage for select weight-management therapies. Effective October 1, 2026, Zepbound returns as a preferred option on template formularies for sponsors that elect c...
comparative effectiveness research
Integration of Comparative Effectiveness Research into Drug Pricing Frameworks
Contemporary comparative effectiveness research plays a vital role in supporting federal and state drug pricing programs by highlighting real-world benefits, yet persistent challenges and unclear guidance continue to limit its integration. Core principles of evidence evaluation, research question...
Conversational Agent Interventions
Therapeutic Impact of Conversational Agent Interventions on Mental Health
Conversational Agent Interventions demonstrate measurable benefits for mental health, according to a meta-analysis of 48 randomized controlled trials involving 28,071 participants that found both AI-based and rule-based agents produced small-to-moderate reductions in depression (SMD −0.27), anxie...